Question
Compare sickle cell anaemia and thalassemia in terms of their molecular cause, type of inheritance, symptoms, and populations affected.
Solution — Step by Step
Both disorders affect haemoglobin (Hb), the oxygen-carrying protein in red blood cells. Normal adult haemoglobin (HbA) consists of two alpha () chains and two beta () chains: .
Disorders affecting these chains lead to abnormal haemoglobin function and red blood cell problems — collectively called haemoglobinopathies.
Molecular cause: A single point mutation (missense mutation) in the gene for the beta-globin chain. At position 6 of the beta chain, glutamic acid (a charged amino acid) is replaced by valine (a nonpolar amino acid).
Normal: chain codon GAG → Glutamic acid
Sickle: chain codon GTG → Valine
This single amino acid change causes the HbS (sickle haemoglobin) to polymerize into long chains when deoxygenated. The long HbS polymers distort the red blood cell into a sickle (crescent) shape.
Consequences: Sickle cells:
- Block small blood vessels (causing painful “crises”)
- Are fragile and destroyed quickly → anaemia
- Cannot carry oxygen efficiently
Inheritance: Autosomal recessive.
- (homozygous): sickle cell disease — severe symptoms
- (heterozygous): sickle cell trait — usually asymptomatic; protected from malaria
- (normal): neither disease nor malaria protection
Affected populations: Common in sub-Saharan Africa, the Mediterranean, Middle East, and India — all regions where malaria is or was historically endemic.
Molecular cause: Mutations in the genes for alpha-globin or beta-globin chains that reduce or eliminate production of that chain. Unlike sickle cell (which produces an abnormal chain), thalassemia produces too little of a normal chain.
Types:
- Beta-thalassemia: Mutations in the beta-globin gene reduce (β+) or eliminate (β0) beta-chain production.
- Alpha-thalassemia: Deletions in alpha-globin genes (there are normally 4 copies — 2 on each chromosome 16).
Without sufficient beta chains, excess alpha chains form unstable aggregates → destroy red blood cell precursors (ineffective erythropoiesis) → severe anaemia.
Severity in beta-thalassemia:
- Thalassemia major (Cooley’s anaemia): both beta genes non-functional (β0/β0). Severe anaemia requiring monthly blood transfusions. Spleen and liver enlarged (extramedullary haemopoiesis). Iron overload from transfusions is a serious complication. Without treatment, life expectancy is short.
- Thalassemia intermedia: moderate symptoms
- Thalassemia minor (trait): heterozygous (β0/β+) or similar — mild microcytic anaemia, usually asymptomatic
Inheritance: Autosomal recessive (for beta-thalassemia). Two carrier parents have a 25% chance of an affected child per pregnancy.
Affected populations: Mediterranean (Greece, Italy — “thalassemia” from Greek “thalassa” = sea), Middle East, South Asia (India, Pakistan), Southeast Asia.
| Feature | Sickle Cell Anaemia | Thalassemia |
|---|---|---|
| Cause | Point mutation (substitution) → abnormal protein | Mutation/deletion → reduced/absent protein production |
| Protein affected | Beta-globin (glutamic acid → valine at position 6) | Alpha-globin or Beta-globin (reduced synthesis) |
| Type of mutation | Qualitative (abnormal protein) | Quantitative (insufficient protein) |
| Inheritance | Autosomal recessive | Autosomal recessive |
| RBC appearance | Sickle/crescent shape | Small, pale (microcytic, hypochromic) |
| Anaemia type | Haemolytic anaemia (fragile cells destroyed) | Ineffective erythropoiesis + haemolytic |
| Malaria protection | Heterozygotes protected | Some protection (alpha-thalassemia) |
| Common in | Africa, Mediterranean, India | Mediterranean, Middle East, South Asia |
| Treatment | Hydroxyurea, bone marrow transplant, gene therapy | Blood transfusions, chelation, bone marrow transplant |
Why This Works
Both disorders demonstrate how mutations in haemoglobin genes cause disease — but through different mechanisms. Sickle cell changes the protein structure (missense mutation creating a polymerizing protein). Thalassemia changes the amount of protein (various mutations in regulatory or coding sequences that reduce expression).
This distinction — qualitative change vs quantitative change — is fundamental in molecular medicine and is a key conceptual difference tested in NEET.
Both disorders also illustrate natural selection maintaining “disease alleles” in populations: heterozygous carriers in malaria-endemic regions have higher fitness than homozygous normal individuals (heterozygote advantage).
Alternative Method
For memorization, focus on the distinguishing molecular feature:
Sickle cell = Substitution (point mutation) → Sickle shape → Single amino acid change
Thalassemia = Too little haemoglobin → Transfusions needed → Twenty-something (many types/severity levels)
NEET frequently tests the distinction between these two disorders with MCQs. Key discriminators: sickle cell = single amino acid change (qualitative mutation); thalassemia = quantitative reduction in chain synthesis. Also remember the RBC morphology: sickle cell → crescentic/sickle shaped; thalassemia → microcytic, hypochromic (small and pale). These morphological differences appear in blood smear interpretation questions.
Common Mistake
Students often say “both diseases affect haemoglobin” without specifying how differently they affect it. In exams, the question is usually asking you to distinguish them — so the critical information is: sickle cell produces abnormal haemoglobin (structural change); thalassemia produces insufficient haemoglobin (quantitative change). Also, students confuse the inheritance pattern — both are autosomal recessive, not X-linked. This is occasionally tested with a pedigree question: “A couple, both carriers of beta-thalassemia, have 4 children — what proportion would you expect to have thalassemia major?” Answer: 25% (1 in 4).